866-997-4948(US-Canada Toll Free)

Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential

Published By :

GBI Research

Published Date : Dec 2010

Category :

Biotechnology

No. of Pages : 77 Pages


GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues in Nanotechnology in Drug Delivery market. 

The report provides a comprehensive insight into the role of Nanotechnology in Drug Delivery. The report also provides a detailed analysis of market characterization of nanotechnology in drug delivery market in terms of its market size, segmentation by key geography types and the major market drivers and barriers. The report also talks about the technological trends over the years in use of nanotechnology in drug delivery.

Scope

The scope of the report includes -

  • Detailed overview of Nanotechnology in Drug Delivery in pharmaceutical industry along with their use, efficiency and limitation.
  • Annualized market data from 2007 and forecast forward till 2016 along with segmentation by geography.
  • Key market drivers and restraints shaping the Nanotechnology in Drug Delivery market.
  • Competitive landscape analysis with competitive profiling of leading companies.
  • Analysis of partnership deals from 2006 to 2010
  • Analysis of M&A deals from 2005 to 2010 along with segmentation by value geography and companies.

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
  • Develop better strategies for Nanotechnology in Drug Delivery market by understanding the market dynamics.
  • Develop market-entry and market expansion strategies by identifying the key development area
  • Understand the factors shaping the Nanotechnology in Drug Delivery
  • For understanding the technological trends in the market.
  • Identify the key players best positioned to take the advantage of the opportunities in the global market.
  • Exploit partnership and acquisition opportunities by identifying the products that could fill the portfolio gaps.
Table of Content

1 Table of Contents

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Nanotechnology in Drug Delivery - Introduction
2.1 Introduction
2.2 GBI Research Report Guidance

3 Application of Nanotechnology in Drug Delivery
3.1 Current Applications of Nano-enabled Drug Delivery
3.1.1 Nano-engineered drugs
3.1.2 Nano-carriers
3.2 Future Applications of Nano-enabled Drug Delivery
3.2.1 Gene and Vaccine Delivery
3.2.2 Controlled-Release Devices
3.2.3 Increased Biocompatibility
3.2.4 Improved Drug Bioavailability and Solubility
3.2.5 Applied Diagnosis, Etiology, Prognosis and Therapy (ADEPT)
3.2.6 Tissue Specific Delivery

4 Nanotechnology in Drug Delivery - Case Studies
4.1 Abraxis Bioscience, Inc. - Paclitaxel-Albumin Nanoparticles (Abraxane)
4.2 Nanospectra Biosciences- AuroShell Particles
4.3 Calando Pharmaceuticals, Inc. - RONDEL Technology
4.4 Starpharma Holdings, Ltd. - Dendrimer-Based VivaGel
4.5 Mersana Therapeutics: Fleximer - Camptothecin Conjugate
4.6 Elan Corporation - NanoCrystal Technology

5 Nanotechnology in Drug Delivery - Market Characterization
5.1 Introduction
5.2 Nano-enabled Drug Delivery Market Drivers
5.2.1 Clinical Benefits of Nano-enabled Drug delivery
5.2.2 Value Addition to Existing Pharmaceutical Products through Reformulation
5.2.3 Strong Pipeline Portfolio
5.3 Nano-Enabled Drug Delivery Market Barriers
5.3.1 Poor R&D Facilities and Time Gap between Research and Commercialization
5.3.2 Lack of Consistent Policy on Technology Transfer and Lack of Capacity to Produce Products
5.3.3 Regulatory Hindrance
5.4 Opportunity and Unmet Need - Drug Delivery
5.4.1 Opportunities
5.4.2 Unmet Need
5.5 Selected Nano-Enabled Therapeutics Approved by the FDA
5.5.1 Doxil (Caelyx)
5.5.2 Abraxane
5.5.3 AmBisome
5.5.4 Diprivan
5.5.5 Triglide
5.5.6 Myocet
5.5.7 DepoCyt
5.5.8 DaunoXome
5.5.9 Estrasorb
5.5.10 Macugen
5.5.11 Abelcet
5.5.12 Adagen
5.5.13 Pegasys
5.5.14 Somavert
5.5.15 Neulasta
5.5.16 Copaxone
5.5.17 Amphotec
5.5.18 PegIntron
5.5.19 Oncaspar
5.5.20 Epaxal
5.5.21 Elestrin

6 Nanotechnology in Drug Delivery - Trend Analysis
6.1 Increasing Government Funding for Nanotechnology R&D
6.2 Increasing Seed and Early-Stage Venture Capital
6.3 Creation of a New Registration Category for Nanotechnology Products within the USPTO
6.4 Genericization and Emerging Business Models Driving a Need for Novel Drug Delivery Methods

7 Nanotechnology in Drug Delivery - Regulatory Landscape

7.1 Introduction
7.2 Europe
7.2.1 REACH Regulation
7.2.2 European Medicines Agency
7.3 The US
7.3.1 Environment Protection Agency
7.3.2 Food and Drug Administration
7.3.3 National Institute of Occupational Safety and Health
7.4 Japan

8 Nanotechnology in Drug Delivery - Pipeline Analysis
8.1 Overview
8.1.1 Pipeline Analysis by Phase

9 Nanotechnology in Drug Delivery - Strategic Consolidations

9.1 Overview
9.2 Mergers and Acquisitions
9.2.1 Mergers and Acquisitions by Geography
9.2.2 Mergers and Acquisitions by Deal value
9.2.3 Mergers and Acquisition Analysis by Deal Type
9.3 Summary of Major M&A Deals
9.3.1 AstraZeneca Acquires MedImmune
9.3.2 Pfizer Completes Acquisition of Wyeth
9.3.3 Celgene Announces To Acquire Abraxis BioScience
9.3.4 Amgen Acquires Abgenix
9.3.5 Teva Pharmaceutical Acquires Ivax
9.4 Licensing Agreement
9.4.1 Deals by Year of Consolidations
9.4.2 Deals by Geography
9.4.3 Deals by Deal value
9.5 Summary of Major M&A Deals
9.5.1 AstraZeneca Enters Into Collaboration and Licensing Agreement with Targacept
9.5.2 AstraZeneca Enters into Licensing Agreement with Rigel Pharmaceuticals
9.5.3 Isis Pharmaceuticals Enters Into Licensing Agreement with Genzyme
9.5.4 Nektar Therapeutics Enters Into Licensing Agreement with AstraZeneca
9.5.5 Abraxis Enters Into License Agreement With ProMetic Life Sciences

10 Nanotechnology in Drug Delivery - Future Players
10.1 Overview
10.2 Abraxis Bioscience (Abraxis)
10.2.1 Overview
10.2.2 Business Description
10.2.3 Product Portfolio
10.3 AlphaRx Corporation
10.3.1 Overview
10.3.2 Business Description
10.3.3 Product Portfolio
10.4 Camurus AB
10.4.1 Overview
10.4.2 Product Portfolio
10.5 Eurand
10.5.1 Overview
10.5.2 Business Description
10.5.3 Product Portfolio
10.6 NanoBio Corporation
10.6.1 Overview
10.6.2 Product Portfolio
10.7 NanoCarrier
10.7.1 Overview
10.7.2 Product Portfolio

11 Nanaotechnology in Drug Delivery - Appendix
11.1 Market Definitions
11.2 Abbreviations
11.3 Research Methodology
11.3.1 Coverage
11.3.2 Secondary Research
11.3.3 Primary Research
11.3.4 Expert Panel Validation
11.4 Contact Us
11.5 Disclaimer
11.6 Sources

List of Table


Table 1: Elan Pharmaceutical, Drugs Based on NanoCrystal Technology, 2010 15
Table 2: Nanotechnology in Drug Delivery, Global, Regulatory Filing Clinical Pipeline, 2010 50
Table 3: Nanotechnology in Drug Delivery, Global, Phase III Clinical Pipeline, 2010 51
Table 4: Nanotechnology in Drug Delivery, Global, Phase II Clinical Pipeline, 2010 51
Table 5: Nanotechnology in Drug Delivery, Global, Phase I Clinical Pipeline, 2010 52
Table 6: Nanotechnology in Drug Delivery, Global, Preclinical Pipeline, 2010 53
Table 7: Nanotechnology in Drug Delivery, Global, Discovery Pipeline, 2010 54
Table 8: Abraxis BioScience, Inc., Nano-Enabled Drug Delivery Pipeline Products, 2010 67
Table 9: AlphaRx Corporation, Inc., Nano-enabled Drug Delivery Pipeline Products, 2010 69
Table 10: Camurus AB, Inc., Nano-enabled Drug Delivery Pipeline Products, 2010 70
Table 11: Eurand, Inc., Nano-enabled Drug Delivery Pipeline Products, 2010 71
Table 12: NanoBio Corporation, Inc., Nano-enabled Drug Delivery Pipeline Products, 2010 72
Table 13: NanoCarrier, Inc., Nano-enabled Drug Delivery Pipeline Products, 2010 73

List of Chart


Figure 1: Nanotechnology in Drug Delivery, Comparison of General and Nano-enabled Drugs, 2010 7
Figure 2: Nanotechnology in Drug Delivery, Current Application of Nanotechnology in the Pharmaceutical Industry, 2010 9
Figure 3: Nanotechnology in Drug Delivery, Future Application of Nanotechnology in Drug Pharmaceutical Industry, 2010 11
Figure 4: Nanotechnology in Drug Delivery, Global, Driver and Restraints, 2010 17
Figure 5: Nanotechnology in Drug Delivery, Opportunity and Unmet Needs, 2010 19
Figure 6: Nanotechnology in Drug Delivery, Trend Analysis, 2010 40
Figure 7: Nanotechnology in Drug Delivery, Challenges Facing Regulators Regarding Nanotechnology 43
Figure 8: Nanotechnology in Drug Delivery, Global, Pipeline by Therapy Area (%), 2010 49
Figure 9: Nanotechnology in Drug Delivery, Global, Pipeline by Phase (%), 2010 50
Figure 10: Nanotechnology in Drug Delivery, Global, M&A Deals by Geography (%), (2006-2010) 55
Figure 11: Nanotechnology in Drug Delivery, Global, M&A Deals by Deals Value (%), 2006-2010 56
Figure 12: Nanotechnology in Drug Delivery, Global, M&A Deals by Deals Type (%), 2006-2010 57
Figure 13: Nanotechnology in Drug Delivery, Global, Licensing Agreements by Years of Consolidation (%), 2006-2010 60
Figure 14: Nanotechnology in Drug Delivery, Global, Licensing Agreements by Geography (%), 2006-2010 61
Figure 15: Nanotechnology in Drug Delivery, Global, Licensing Agreements by Deals Value (%), 2006-2010 62
Figure 16: Nanotechnology in Drug Delivery, Global, Clinical Pipeline by Company, 2010 65

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *